What is Precision Epigenomics?
Precision Epigenomics operates at the intersection of biotechnology and preventative medicine, focusing on the development of non-invasive liquid biopsy assays. The company's core value proposition lies in its ability to detect multiple cancer types at nascent stages, a capability that significantly improves patient prognosis and reduces long-term healthcare expenditures. By utilizing sophisticated epigenetic analysis, the firm offers a diagnostic framework that is both rapid and accessible, addressing the critical need for reliable early-warning systems in oncology. Their market position is defined by a commitment to clinical excellence and the democratization of high-precision health monitoring, effectively bridging the gap between complex genomic research and routine clinical practice.
How much funding has Precision Epigenomics raised?
Precision Epigenomics has raised a total of $4.2M across 3 funding rounds:
Other Financing Round
$2.4M
Series A
$1.5M
Debt
$265K
Series A (2024): $1.5M with participation from Shaffer Capital
Other Financing Round (2024): $2.4M, investors not publicly disclosed
Debt (2025): $265K, investors not publicly disclosed
Key Investors in Precision Epigenomics
Shaffer Capital
Shaffer Capital provides comprehensive financial planning and investment management services, focusing on customized strategies that promote long-term capital growth for businesses and families.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Precision Epigenomics?
Looking ahead, Precision Epigenomics is poised to leverage its recent capital to scale its laboratory infrastructure and expand its clinical trial footprint. The strategic roadmap emphasizes the integration of its diagnostic tools into broader healthcare networks, aiming to establish EPISEEK as a primary screening modality. As the company navigates the complexities of regulatory approval and market penetration, the focus will remain on optimizing the cost-efficiency of its testing protocols. This phase of growth is expected to involve significant investment in data analytics and machine learning to further refine the sensitivity and specificity of its epigenetic detection models, ensuring the firm remains at the vanguard of the precision medicine revolution.
See full Precision Epigenomics company page
